Biofrontera Inc. (BFRI)
0.80
-0.04 (-4.76%)
At close: Apr 14, 2025, 3:49 PM
0.81
1.37%
After-hours: Apr 14, 2025, 07:55 PM EDT
-4.76% (1D)
| Bid | 0.77 |
| Market Cap | 7.1M |
| Revenue (ttm) | 37.3M |
| Net Income (ttm) | -17.76M |
| EPS (ttm) | -3.22 |
| PE Ratio (ttm) | -0.25 |
| Forward PE | -0.92 |
| Analyst | Buy |
| Ask | 0.84 |
| Volume | 6,392 |
| Avg. Volume (20D) | 125,195 |
| Open | 0.83 |
| Previous Close | 0.84 |
| Day's Range | 0.77 - 0.84 |
| 52-Week Range | 0.65 - 2.22 |
| Beta | 0.37 |
About BFRI
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-m...
Sector Healthcare
IPO Date Oct 29, 2021
Employees 92
Stock Exchange NASDAQ
Ticker Symbol BFRI
Website https://www.biofrontera.us.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BFRI stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 775.00% from the latest price.
Stock ForecastsNext Earnings Release
Biofrontera Inc. is scheduled to release its earnings on May 14, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
-16.5%
Biofrontera shares are trading lower after the com...
Unlock content with
Pro Subscription
3 months ago
+6.31%
Biofrontera shares are trading higher after the company announced the last patient completed the 1 year follow-up of study ALA-BCC-CT013 in December 2024.
